Company Overview
Company Type: Public Company
Website: www.biosyent.com
Number of Employees: -
Ticker: RX (TSXV)
Year Founded: 2006


Business Description
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
28.7
Market Capitalization
95.8
TEV/Total Revenue
2.4x
EBITDA
6.6
Total Enterprise Value
69.1
TEV/EBITDA
10.2x
EBIT
6.4
Cash & ST Invst.
27.9
P/Diluted EPS Before Extra
18.9x
Net Income
5.3
Total Debt
1.3
Price/Tang BV
3.0x
Capital Expenditure
0.0
Total Assets
39.5
Total Debt/EBITDA
0.2x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-03-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
0.10
0.10
0.21
0.38
0.30
Revenue (mm)
8.20
8.50
31.10
35.60
33.35
EBITDA (mm)
1.80
1.70
6.80
8.00
7.40

Forward Multiples (Current FY)

Price/Earnings
38.57x
TEV/REV
2.22x
TEV/EBITDA
10.17x

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
8.00
Potential Upside
(1.23)%


Key Professionals
Name
Title
Goehrum, René C.
Chairman, CEO & President
March, Robert J.
VP of Finance & CFO
van der Mark, Joost 
Vice President of Corporate Development
Atwal, Neelu 
Director of Human Resources
D'Souza, Alfred 
Advisor

Key Board Members
Name
Title
Goehrum, René C.
Chairman, CEO & President
Arcuri, Joseph 
Independent Director
Elford, Sara
Independent Director
Lockhard, Peter D.
Lead Independent Director
Andrews, Larry 
Independent Director
Wilton, Stephen 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
2476 Argentia Road Suite 402 | Mississauga, ON | L5N 6M1 | Canada
Phone: 905-206-0013   Fax: 905-206-1413

Current and Pending Investors
Fidelity Management & Research Company LLC, Intrepid Equity Finance Ltd., Investment Arm

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 8.10
Market Cap (mm)
95.8
Open
 8.02
Shares Out. (mm)
11.8
Previous Close
 8.10
Float %
77.5%
Change on Day
0.24
Shares Sold Short (mm)
-
Change % on Day
3.1%
Dividend Yield %
2.0%
Day High/Low
 8.10/ 8.02
Diluted EPS Excl. Extra Items
0.43
52 wk High/Low
 8.20/ 6.24
P/Diluted EPS Before Extra
18.89x
Volume (mm)
0.0017
Avg 3M Dly Vlm (mm)
0.0028
Beta 5Y
0.79


 
Delayed Quote** | Last Updated on Oct-03-2023 12:00 AM (GMT-5)
TSXV:RX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
BioSyent Pharma Inc.

United States and Canada
-
-
-
-
BioSyent Pharma International Inc

United States and Canada
-
-
-
-
Hedley Technologies (USA) Inc

United States and Canada
-
-
-
-
Hedley Technologies Ltd.

-
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-13-2022
-
Buyback
Target
BioSyent Inc. (TSXV:RX)


-
Dec-13-2021
-
Buyback
Target
BioSyent Inc. (TSXV:RX)


2.45
Dec-11-2020
-
Buyback
Target
BioSyent Inc. (TSXV:RX)


0.89
Dec-11-2019
-
Buyback
Target
BioSyent Inc. (TSXV:RX)


2.22
Dec-04-2018
Nov-20-2019
Buyback
Target
BioSyent Inc. (TSXV:RX)


5.20
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-30-2023
Ex-Div Date (Regular)
BioSyent Inc., 0.04 (CAD), Cash Dividend, Aug-30-2023
Aug-22-2023
Buyback Tranche Update
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022.
Aug-22-2023
Dividend Affirmations
BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023
Aug-22-2023
Earnings Calls
BioSyent Inc., Q2 2023 Pre Recorded Earnings Call, Aug 22, 2023
Jun-01-2023
Ex-Div Date (Regular)
BioSyent Inc., 0.04 (CAD), Cash Dividend, Jun-01-2023


Advisors
Most Recent Auditor
MNP LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:17 AM
RX
Biosyent Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:37 AM
RX
ValuEngine - Toronto Quantitative Stock Report for RX
Reports
5
CFRA Equity Research

Oct 01, 2023 10:37 AM
RX
BioSyent Inc.
Reports
9
GlobalData

Sep 11, 2023 03:36 AM
RX
BioSyent Inc (RX.CVE) - Financial Analysis Review
Reports
138
S&P Global Compustat

Sep 07, 2023 02:59 AM
RX
Biosyent Inc 2023_09_07
Reports
14
MarketLine

Aug 31, 2023 06:01 AM
RX
BioSyent Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
21
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 15, 2023 06:00 PM
RX
Will Biosyent Inc Deliver Long-Term Returns?
Ratings Change*
12
S&P Global Compustat

Jul 06, 2023 02:40 AM
RX
Biosyent Inc 2023_07_06
Reports
14
GlobalData

Jun 09, 2023 04:56 AM
RX
BioSyent Inc (RX.CVE) - Financial Analysis Review
Reports
136
S&P Global Compustat

Jun 01, 2023 03:07 AM
RX
Biosyent Inc 2023_06_01
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


FAX Capital Corp.

2,146,100

18.15

17.4

Apr-13-2023


1069867 Ontario Ltd

1,087,761

9.20

8.8

Apr-13-2023


Goehrum, René C.

987,931

8.36

8.0

Apr-13-2023


Intrepid Equity Finance Ltd., Investment Arm

500,000

4.23

4.1

Apr-13-2023


Canadian Western Trust, Asset Management Arm

210,900

1.78

1.7

Jun-30-2023


Lockhard, Peter D.

180,714

1.53

1.5

Jun-30-2023


Grandeur Peak Global Advisors, LLC

161,287

1.36

1.3

Jul-31-2023


Arcuri C.A., CPA, Joseph 

107,371

0.91

0.9

Oct-02-2023


Wilson, Kevin 

62,317

0.53

0.5

Jun-02-2023


Ashrafi, Seyed Ahmad

49,415

0.42

0.4

Mar-31-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Canadian Western Trust, Asset Management Arm
210,900
21,458
Lockhard, Peter D.
180,714
3,433
van der Mark, Joost 
47,930
2,000
Arcuri C.A., CPA, Joseph 
107,371
287

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Wilson, Kevin 
62,317
(1,088)
Andrews, Larry 
9,051
(1,056)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Distribution of Cardiovascular Products (Future), Distribution of Combogesic, Distribution of Proktis-M Rectal Suppositories, Distribution of RepaGyn, Distribution of Tibella, Insecolo, Protect-It


Upcoming Events
Date/Time
Type
Nov-17-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-22-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
17 KB
Aug-22-2023
Jun-30-2023
BioSyent Inc. (TSXV:RX)
SEDAR
Interim Financial Statements
434 KB
Aug-22-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
70 KB
Aug-15-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
16 KB
Aug-08-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
98 KB
Jul-06-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
27 KB
Jun-20-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
20 KB
May-31-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
17 KB
May-26-2023
Mar-31-2023
BioSyent Inc. (TSXV:RX)
SEDAR
Interim Financial Statements
369 KB
May-26-2023
-
BioSyent Inc. (TSXV:RX)
SEDAR
News Releases
60 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Arcuri C.A., CPA, Joseph  (Independent Director)
Oct-02-2023
Common Shares
287
2,259
Derivative Exercise and Retained Stock
0.27
Multiple
Lockhard, Peter D. (Lead Independent Director)
Oct-02-2023
Common Shares
1,148
9,035
Derivative Exercise and Retained Stock
0.64
Multiple
Lockhard, Peter D. (Lead Independent Director)
Oct-02-2023
Common Shares
(2,297)
0
Other Disposition
(1.26)
Multiple
Andrews, Larry  (Independent Director)
Oct-02-2023
Common Shares
(2,123)
0
Other Disposition
(20.99)
Multiple
Andrews, Larry  (Independent Director)
Oct-02-2023
Common Shares
1,061
8,351
Derivative Exercise and Retained Stock
15.31
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Goehrum, René C.
Chairman, CEO & President
905-206-0013
905-206-1413
rgoehrum@biosyent.com
Arcuri, Joseph 
Independent Director
905-206-0013
905-206-1413
jarcuri@nrstor.com
Elford, Sara
Independent Director
905-206-0013
905-206-1413
-
Lockhard, Peter D.
Lead Independent Director
905-206-0013
905-206-1413

Andrews, Larry 
Independent Director
905-206-0013
905-206-1413

Wilton, Stephen 
Independent Director
905-206-0013
905-206-1413

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Goehrum, René C.
Chairman, CEO & President
905-206-0013
905-206-1413
rgoehrum@biosyent.com
March, Robert J.
VP of Finance & CFO
905-206-0013
905-206-1413

van der Mark, Joost 
Vice President of Corporate Development
905-206-0013
905-206-1413

Atwal, Neelu 
Director of Human Resources
905-206-0013
905-206-1413

D'Souza, Alfred 
Advisor
905-206-0013
905-206-1413

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
